A4 AMYLOID BETA
Also known as
Amyloid-beta peptide studied as a disease target and biomarker in Alzheimer's research. Investigated for cognition; preliminary evidence grade — no published interventional RCTs of administering it as a therapeutic.
Evidence
Animal or in-vitro only
Risk band
Known AEs, monitoring advised
Research goals
Summary
Amyloid-beta (Aβ) is a peptide generated by sequential cleavage of amyloid precursor protein (APP) by γ-secretase, and its aggregation-prone 42-residue form (Aβ42) has long been regarded as the pathogenic entity in Alzheimer's disease [3]. Far from being a therapeutic, it is studied as a disease target: Alzheimer's is described as a consequence of failure to clear Aβ from the brain, and rare inherited APP/γ-secretase mutations cause early-onset familial disease [3,4]. Its accumulation can now be detected in preclinical and prodromal phases via cerebrospinal fluid biomarkers and PET, and environmental factors such as nanoplastics can enhance Aβ aggregation and neurotoxicity [1,4]. The provided literature contains no interventional trials of administering Aβ as a therapy; current approved drugs only ameliorate symptoms without modifying the underlying process [4]. Evidence for Aβ as an administered therapeutic is therefore essentially absent — this is a target molecule, not a treatment.
Sources
- 1. Impact of nanoplastics on Alzheimer 's disease: Enhanced amyloid-β peptide aggregation and augmented neurotoxicity Journal of hazardous materials, 2024.
- 3. In search of pathogenic amyloid β-peptide in familial Alzheimer's disease Progress in molecular biology and translational science, 2019.
- 4. Alzheimer's disease Nature reviews. Disease primers, 2015.
For educational purposes only.